Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of a recombinant trivalent rotavirus subunit vaccine in healthy infants and young children
CTR20211825Phase 2Active
- Sponsor
- MAXVAX Biotechnology
- Start
- Jan 2023
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant trivalent subunit rotavirus vaccine in rotaviral diarrhea, sponsored by MAXVAX Biotechnology. Started Jan 2023; status: active.
02
Drugs
recombinant trivalent subunit rotavirus vaccine
03
Conditions
rotaviral diarrhea
Beyond the preview
Go deeper on CTR20211825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211825.